opportunity really Thanks, Mike. words work few closely years. with past and to these appreciate you the kind I the
conduct English, our Officer. Trish will I Chief Financial recently want Chief smooth been as know also to be as has Trish a I and what be fabric Accounting the of to be to serving Interim am thank Officer am excited of transition. is this welcome I and to will responsibility. culture that our for by most to the who while served forward for taking the for of and work new placing Let preserve the family to forward valuable Cardinal new a ingrain I would how helped I I grateful the permanent look you, continuing me like start an the her you've contributions to the years. our the in for capacity look years. we leadership many this trust Directors also the over me. company hope into the Health over CFO. search external a Board organization, I I and member saying with on XX to confidence Mike,
growth and performance points incurred incremental summarize for the our and effects Before of this inflation year. into Pharma business more industry-wide well segment, technology step a impacted dynamics, We Medical X%, long-term past as financial the the business impact we The for significant back both consistent our the grew inflationary targets. significantly our of while quarter, key with the by our these experienced original was me investments. results. stepping which details our the Within as guidance let drove on year
pricing plus X% the fiscal in which strong 'XX. compounded However, we a Underlying increased inflationary flexibility. mitigation annual of chain all growth this of operating in results on that year and focus significant have impacts to was plan a present global flow, actions cash mitigates past an including place, additional and today you supply by these results will constraint financial
absolutely for fiscal We to repurchases value intend deploy share to shareholder on funds 'XX. and additional are incremental focused these
While the key metrics we underlying commit I'm today, continue details plans environment, to of you further dynamic and increased excited share with to provide remain in our a performance. [indiscernible] to and drivers our
quarter, So Segment and higher to from the brand sales chain Pharma from beginning supply with driven new and increased quarter results the in offset to fourth let's Fourth specialty existing contribution some costs. X. Slide segment branded net now XX% and $XXX profit program million $XX our by a billion, turn to XX% on growth inflationary by the revenue sales details of pharmaceutical performance driven increased customers. driving PD by mix, generics partially
prior this reflects noted, to due a adjustments. comparison the inventory As we've year also favorable previously
including Red consistent our experience program, During dynamics. Oak, market quarter, saw the and strong performance to generics continued
into labor, saw we in that Regarding which expectation costs, we impacts the supply to areas inflationary continue expect chain next year. and
incurred also $XX decrease supporting litigation opioid-related with in cost opioid growth. costs. saw legal in approximately a sales higher we million We ongoing And progress of matters,
was to X. mostly on products contribution lower and the chain volumes. divestiture million business lower and constraints products from offset due reserve decreased Medical impacts, XX% and and billion revenue Fourth Slide inventory net Medical and due to of quarter basis, prior to divestiture. the by year-over-year inflationary of $X.X loss inflationary $XXX supply favorable constraint was distribution the chain On Cordis fourth the impacts $XX million to a the PPE the net supply global and to quarter a on distribution. segment Turning PPE Cordis in the of year global comparison
'XX and the our supply mitigation This approximately approximate During for constraints. actions, million which plans distribution and a million from includes impact increases brand from price beyond and on initial our mitigation our effect impact that Health wave on in $XXX I'll $XXX net into reflects business million Cardinal offset chain elaborate in X shortly. saw of went $XX of March. quarter, approximate incremental our categories fiscal gross and an further back inflation products
primarily QX previously expected. This past declines. a back, medical than has reflects lower for significantly quarter had of this We distribution results our constraints continues it mentioned, dynamic fourth from overall driven believe PPE We a inventory highly Stepping experienced Demand and to we in customer fluctuated to including the pandemic. customers' during As the be over some levels lower saw came years. lower the category-specific couple PPE. softness primarily and extent, business, contribution supply and a further by PPE in as and volume higher environment, our QX volumes exited reflects losses we lesser products
products. conviction which includes strong have proposition, in differentiated brands value overall clinically and leading to our continue We
PPE portfolio, you'll represents Cardinal context, Health Slide as XX. on sales see our brand approximately For in XX% overall of
to the Interest plan compensation of a in our decrease million line. by the other $XX year. deferred to below in Moving million increased and prior gains value investments compared to due $XX
deferred neutral gains corporate other [indiscernible] in As net reported compensation or offsetting and are our bottom SG&A interest line. losses fully and to
to share. equity per impacted increase The in the expense of EPS reduction debt other by write-down $X.XX offset interest an Additionally, due fourth investment onetime was actions. partially quarter, lower a in by
repaid June at As $XXX XXXX we indicated, of million the remaining maturity. notes
higher year. result was $X.XX, Our The rate segment an fourth fourth quarter at primarily of pharma the XX.X%, than prior the quarter growth finished EPS net effective profit. X increase percentage XX%, tax in reflecting approximately points of
largely a partially to XX% $XXX the net for items X%, from results driven our the chain chain guidance quarter. global $XXX million, related Total decreased reflecting to million, Cordis transitioning our due decreased segment. the fourth note, affecting sales Now supply the this increased Pharma costs, IT equity savings in the million growth, inflationary and and higher $XXX to in to reflects and to to increased offset our benefits by and company Of due year-over-year higher XX% Fiscal divestiture. revenues approximately X% in divestiture by medical, costs Pharma supply the XX%, margin other earnings 'XX headwind Interest the of primarily to segment constraints cost Operating previously investment to impacts which Gross to inflationary write-down mostly by support quarter. mentioned initiatives. SG&A Cordis growth. primarily profit year. increased than offset consolidated came due investments
result net The finished $X.XX. Our annual 'XX XX.X%. tax effective EPS rate fiscal of at was
tax operating Now cash we balance timing In billion of billion. includes fiscal sheet. previously and 'XX, robust flow $X.X favorable working of turning capital. defined nearly refund This $X of the to generated the
in primarily Additionally, approximately flow. our which approximately operating we of 'XX annual second payment QX $XXX opioid settlements. million to settlement in we the payments, $XXX 'XX, under made related litigation will agreement fiscal cash made fiscal In in July, opioid million, be national reflected
year through shareholders balanced, future with on and in debt no approximately back credit dividends. million cash returned borrowings $XXX into position in approximately We growth, billion, capital and does our invested business of on down manner. ended $X.X leverage share outstanding which to and of a a paid focused year, timing million drive reduce disciplined reflect we deploying the We shareholder-friendly the to CapEx $X.X repurchases favorability with some are billion $XXX This facilities. to
IT on technology $XX to $X.X increased year volumes offset on be the primarily segment supply reflecting approximately segment's with costs. the headwind and incremental fiscal billion, XX% revenue Pharma year. program $XXX inflationary full beginning the As improvement to volumes a tailwind basis. in improved profit XX. fourth in compared offset enhancements year-over-year from the To performance increased generics driven partially was helpful, Pharma 'XX, investments and in investments an drivers X% prior and effectively the quarter. for million to each from Pharma results, by by chain with consistent This billion, Slide
saw approximate the we million chain headwind Additionally, costs, $XX primarily of in supply inflationary an half year. the from second
distribution volumes due medical , due primarily lower the products and decreased profit constraints to Moving XX. X% were $XXX Segment the by partially impacts XX% XX extent, primarily Slide global solutions. to inflationary in to growth lesser and decreased net a to distribution. divestiture the in chain Fiscal To Cordis offset in business. to at-home million, revenue supply Medical of on products
PPE the Additionally, reserve business. to offset PPE the a lower the prior and of contribution the was comparison from Cordis inventory divestiture year favorable by
expect we per before fiscal the between for earnings enterprise, for at maturity. $X.XX the following $XXX in we to the assumes interest paydown which Now million, First, March $XXX other $X.XX, million which expect share range and XXXX reflects Slide $XXX debt our million XX, of for notes or 'XX approximately assumptions: guidance. On to the in
We over we to the allocation excludes and any expect to in complete nonrecurring supporting which $X.X the free are million to to share billion billion adjust anticipate average payments a other litigation tax diluted range the to $X.X range rate items. priorities, capital significant our and the reflecting $XXX of plan or of non-GAAP XX%. and repurchases shares course million, unusual assuming year. We effective in And our $X outstanding billion, $XXX $X flow in between weighted between billion of XX% cash
XX%, the range customers. on in segments, XX, and revenue by of with growth PD driven As Slide in and new Pharma beginning specialty the we for to existing growth XX% net expect
segment expect the X% X% range assumptions. following on of profit based in We key to growth the
of The with We Continuation result along volumes of $XX million inflationary approximate in in technology pharmaceutical completion ERP market seen continued of supply $XX stability last program. consistent within expect year. headwind generics first in quarters the be half approximate should dynamics the chain million primarily our should costs the an tailwind. X enhancements we've in overall the
increased contributions million adjunctive terms $XX opioid-related 'XX, biosimilars. And expect legal implementation areas, tailwind. in relief of a approximately of the from in $XX including specialty, we our settlements initial primarily growth costs, We million fiscal including costs see for
significantly of chain a in the which 'XX be Medical, year-over-year of year-over-year year, from couple weighted, inflationary to Similar first the segment the back-half half. the points fiscal impact to to supply reflects . profit last we costs primarily moving expect Before Pharma growth
profit in Specifically, segment and first expect million. between we year, quarter $XXX million $XXX the next of
be may While puts provide we guidance, we last helpful quarters. color typically do not additional quarterly and several over the the given thought takes
Now turning to Slide Medical on XX.
We testing the volumes. to expect in to range PPE and lab to sales X% revenue X% decline of due lower
reflecting the a growth from of XX% ranging assumptions. profit XX%, following decline segment expect to We of
This or and expect partially an mitigation chain contracting. million in inflation, mitigation 'XX from of gross by approximately year-over-year commercial including basis. approximate a We a similar chain on net actions and supply a pricing minimal million global fiscal our impact $XXX supply impact impact of inflation million $XXX constraints and $XXX global from offset actions, constraints, evolving assumes
While and by in still encouraged some elevated the we're significantly freight relative recent historical drivers of spot certain to levels, international rates such as cost commodities. improvements
are been As in a have costs X historically P&L to product results and capitalized X delay. quarter these reminder, our on reflected a
in elongated However, the supply period X is closer current of it chains, quarters. to
and is of impact supply fiscal of first quarter global will in chain the assumption the couple years. decrease peak inflation next Our in of that current 'XX constraints the gradually over
over the year, increases are the of with the that along additional 'XX. pricing of at went course of Additionally, into fiscal start ways we implementing effect the actions
that rate from offset constraints. at of the actions expect exit XX% we continue run the chain our and global fiscal will gross impact We to 'XX, mitigation least as supply of inflation
other terms fiscal and of assumptions for In 'XX. key medical
As the from the in normalize through of an in of operating the PPE year half normalize, to the PPE improvement to exit first environment million the expect we margins. plan and continues for majority an We sell PPE tailwind approximate to higher-cost we as year. margins $XX
from to similar PPE lower We tailwind headwind expect testing be a volumes. by offset the lab
primarily a incentive increased approximately Home fiscal compensation growth million underperformance. expect We headwind we anticipate also from Solutions. from finally, And our of strategic 'XX areas, following contributions re-baseline $XX at be similar in 'XX total fiscal cadence, segment year. are prior to reverse expect we 'XX, assuming profit quarterly On do versus cadence fiscal a of while the Medical's the the we
Specifically, the to profit we $XX quarter, ranging loss profit $XX million million. first in segment expect from a of of
XX% We impact approximately of our to the gross approximately expect offset through quarter mitigation of $XXX chain global million, first this and in be the inflation actions. supply constraints
rest supply 'XX, chain the second around half inflation year, assumptions we the the of majority fiscal our profit segment and expect primarily substantial the As sequencing for of PPE. global of the reflects in fourth This quarter. come in to inflation, constraints, particularly mitigation
While there long-term combined are previously reiterating outlook our double-digit our periods. are we 'XX, yield confident and our dividend for parts moving in growth our EPS over long-term targets and many announced in businesses longer fiscal normalized and for
million X introducing impact fiscal plan that areas Additionally, to supply driven gross and in we at introducing chain segment supply are fully initiatives profit least constraints. impact of address time through business. our medical by highlights a constraints by and to global the Medical inflation of at the our exit 'XX new of and XX the the 'XX exit least targeting for fiscal global are $XXX Slide improvement performance. improve chain 'XX, We focus are fiscal offsetting we Number plan mitigation to today. target inflation we medical one, mitigate on by half
on to went increases wave price on commencing on X. plan October of X We wave next second categories. the effect more X July Our on
for In adjust in current and they we for distribution Two, and actively language as the addition, are Cardinal brand customers we've to product to dynamics. grow allowing GPOs optimize suppliers, executed flexibility respond price to Health and contracts future certain and and portfolio. distribution working with our greater fee macroeconomic renew, increases
sales Our by offers $X Plan brand to at segment million brands Health focus. billion of $X.X annual includes the profit categories, or will of through clinically rate a X billion years. leading more This and nearly grow brand Cardinal key least Health $XX areas will next growth of portfolio, over Cardinal X differentiated achieved which compounded products. which be incremental X%, growth generate of non-PPE
categories will launching see be Kangaroo platform. next-generation nutritional new feeding We new delivery, and R&D [indiscernible] key we opportunities product such the where as First, in innovation.
investments a targeted surgical and product increased availability of is categories Second such as as result within gloves electrodes.
of For we facility gloves. surgical are construction leading Texas new increased dedicated glove $XXX in our portfolio, supply investing example, for manufacturing for million a to for brand
million total These rates opportunity, drive has Solutions. with primarily Third a growth higher our At and area making continue our top along 'XX. billion growth grown of in have by for excess least core, segment finally, accelerate area to patient at businesses, our $XX is been we've simplification of our now example, focus to at of care profit investments Home Home margin home. around continues is at focus fiscal And a consistently that cost line as our shift into of and to is fourth business $X.X XX% the Solutions, optimization efforts. to businesses
office chain our supply to back at actions fiscal plants, expect manufacturing increased that 'XX. $XX in yield least and savings net centers, productivity million We cost of by distribution
sourcing possible. management driving further focused forward, simplification our and value transportation through and improvement where on manufacturing are Going optimizing we footprint projects,
We exceeding by $XXX enterprise existing fiscal million our 'XX. contribute expect towards cost goal these savings initiatives to
While chain, me have with color investor to our operate highly supply chain products. our diverse We on additional Cardinal self-manufactured revenue number take questions. received the supply a topic brand X/X we coming some approximately let of where from Health share of a of moment a global
of focused responding summary, have In supply introduction in total. own half of of with North are we and believe of measure chain, We points believe revenue we to diverse focus any in progress North forward. provides capabilities, against many from And disruptions continue resilience Cardinal our comes self-manufacturing America the plans going best of and a to the supply these facilities. to brand To American proof measurable today, agility. additional in visibility approximately invested Health our serve importance X chain in global in global each our areas we our customers, on
Distribution, further Pharma maximizing now past several working With and on our with on technology to X,XXX attended first experience over the we Pharmaceutical to prioritizing our our We that latest anchored opportunity customers attention of investing experience. turn and generics time capital focus X Oak, and let's specialty. businesses, working an completed, expertise focus substantially we where Retail been efficiency to over we recently Red capabilities focus innovations. of the productivity, our Business program increasing we core on maximizing on where years, to our PV share for our and our and we've had Conference in scale continue as business customer see margins. strengthening years In enhancements the segment the live continue the by held enhance our wallet primarily Now growth significant in and
manufacturers, services and investment cold create compliance for robust solutions by a rheumatology services. fill central further register downstream specialty the future offers in management Specialty tuck-in services rheumatology increases to capacity which access them we specialty, innovative advisory current to to by office which chain areas These will over drug chance nationwide. support providers therapeutic expansion, we XPL TS. announced see including Bank offerings, We the portal, packaging momentum reimbursement as care GPO had business Vista with also that strengthen online in and are storage through biopharma optimize help would shopping our emerging of are driven We our organization. XXX%. In oncology GPO, acquisition main investing an Upstream their and and evidenced Solutions the cornerstone to continuing growth in for X,XXX our our
to We accessibility. ensure also comfort campaigns in in education biopharma build with common awareness, to solutions clinical technology strong hub our by our investing help are remove biosimilars, continue patient proactively addressing we barriers barriers growth SynXis where to see care. to adoption And and patient customers
and our will your to well 'XX We and come work new while With beyond. and as remain plans continue a done, our to about questions. growth with fiscal the positioned in lot I'm excited XX,XXX that, executing be to work be to biosimilars take In teammates in closing, space I now grow market. to there's excited future of the
